Essen, Germany

David Brückner



Average Co-Inventor Count = 14.1

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2005-2007

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of David Brückner in Medicinal Chemistry

Introduction

David Brückner, an inventive mind based in Essen, Germany, has made significant contributions to the field of medicinal chemistry. With two patents to his name, he focuses on innovative solutions for treating neurodegenerative disorders and cancer. His work is not only groundbreaking but also highlights the potential of chemical compounds in improving health outcomes.

Latest Patents

Brückner's latest patents include notable advancements in the area of substituted imidazotriazines. The first patent describes new substituted imidazotriazines, processes for their preparation, and their use in the production of medicaments aimed at treating and preventing cancer and neurodegenerative disorders, specifically Parkinson's disease and schizophrenia. His second patent involves imidazotriazines utilized as phosphodiesterase inhibitors, emphasizing their application in the treatment of neurodegenerative disorders, particularly Parkinson's disease.

Career Highlights

David Brückner is currently affiliated with Bayer Healthcare Aktiengesellschaft, where he utilizes his expertise to further the company's innovative approaches in healthcare solutions. His research within Bayer underscores the importance of collaboration between advanced chemistry and healthcare applications.

Collaborations

Brückner works alongside esteemed colleagues such as Martin Hendrix and Arno Friedl, fostering a collaborative environment that enhances creativity and innovation within their projects. This teamwork is vital for the development of successful medicinal treatments that have the potential to impact many lives.

Conclusion

David Brückner's contributions to the field of medicinal chemistry through his innovative patents stand as a testament to his dedication and skill as an inventor. His work at Bayer Healthcare Aktiengesellschaft demonstrates the potential for new pharmaceutical solutions to arise from collaborative efforts and innovative thinking. As he continues to advance research in this field, his impact on the medical community will undoubtedly grow.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…